Akari 10-Q: Going-Concern Warning With $5.7M Cash and $24.1M Nine-Month Loss
AKTX has more than doubled off its 52-week low of $3.015 on light trading volume (0.2× avg).
Summary
Akari ended Q3 2026 with $5.7 million of cash and explicit substantial doubt about its ability to continue as a going concern, with runway only into the first quarter of 2027. The nine-month net loss was $24.1 million, including $12.1 million of non-cash impairments.
Key Events · Earnings and Guidance · AKTX
-
Going-Concern Warning on $5.7M Cash
Cash of $5.7 million at September 30, 2026 is not sufficient to fund operations for the one-year period after issuance, raising substantial doubt about going concern; runway is described as only into the first quarter of 2027.
-
Nine-Month Loss Doubles to $24.1M
Net loss for the nine months ended September 30, 2026 was $24.1 million versus $12.0 million a year earlier, driven by $12.1 million of non-cash impairments plus higher R&D spending of $5.6 million versus $1.7 million.
-
$12.1M Non-Cash Impairments Booked
Q1 2026 impairment testing triggered by the market-cap decline produced a $3.7 million write-down of the AKTX-101 IPR&D asset and an $8.4 million goodwill write-off; no impairment was recorded in the third quarter itself.
-
Share Count Nearly Doubles in Nine Months
Ordinary shares outstanding rose to 182,813,169,533 at September 30, 2026 from 90,536,879,533 at December 31, 2025, reflecting the May 2026 private placement, warrant exercises and ELOC draws.
Analysis · AKTX · Life Sciences
Akari closed September 30, 2026 with $5.7 million of cash against a $288.7 million accumulated deficit, and management states plainly that this balance will not fund operations for the twelve months after the filing — substantial doubt about going concern. Runway is now described as only into the first quarter of 2027, so another raise is required almost immediately, and the company has already been funding itself through heavy equity issuance: ordinary shares outstanding went from 90.5 billion at December 31, 2025 to 182.8 billion at September 30, 2026. The nine-month loss of $24.1 million is roughly double the prior-year $12.0 million, inflated by $12.1 million of non-cash impairments ($3.7 million on the AKTX-101 IPR&D asset and $8.4 million on goodwill) taken in the first quarter when the market cap fell. The unremediated material weakness in internal controls, with disclosure controls still deemed ineffective, adds governance risk on top of the cash problem.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 49.5% of the 210 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKTX was trading at $6.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13M. The 52-week trading range was $3.02 to $29.32. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.